AQR Capital Management’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-30,590
| Closed | -$463K | – | 2327 |
|
|
2022
Q3 | $463K | Sell |
30,590
-50,423
| -62% | -$586K | ﹤0.01% | 1817 |
|
|
2022
Q2 | $608K | Buy |
81,013
+41,813
| +107% | +$295K | ﹤0.01% | 1614 |
|
|
2022
Q1 | $357K | Buy |
39,200
+14,520
| +59% | +$112K | ﹤0.01% | 1924 |
|
|
2021
Q4 | $173K | Buy |
+24,680
| New | +$258K | ﹤0.01% | 2106 |
|
|
2018
Q3 | – | Sell |
-4,176
| Closed | -$282K | – | 2351 |
|
|
2018
Q2 | $282K | Sell |
4,176
-7,141
| -63% | -$400K | ﹤0.01% | 2139 |
|
|
2018
Q1 | $614K | Sell |
11,317
-10,074
| -47% | -$563K | ﹤0.01% | 1843 |
|
|
2017
Q4 | $1.28M | Sell |
21,391
-13,687
| -39% | -$830K | ﹤0.01% | 1573 |
|
|
2017
Q3 | $1.71M | Buy |
35,078
+457
| +1% | +$24.9K | ﹤0.01% | 1440 |
|
|
2017
Q2 | $1.82M | Buy |
34,621
+3,715
| +12% | +$173K | ﹤0.01% | 1423 |
|
|
2017
Q1 | $1.4M | Buy |
30,906
+5,206
| +20% | +$232K | ﹤0.01% | 1541 |
|
|
2016
Q4 | $973K | Buy |
+25,700
| New | +$972K | ﹤0.01% | 1705 |
|
|
2015
Q3 | – | Sell |
-49,878
| Closed | -$880K | – | 2287 |
|
|
2015
Q2 | $880K | Buy |
49,878
+20,478
| +70% | +$375K | ﹤0.01% | 1560 |
|
|
2015
Q1 | $921K | Buy |
29,400
+13,100
| +80% | +$380K | ﹤0.01% | 1452 |
|
|
2014
Q4 | $476K | Buy |
+16,300
| New | +$413K | ﹤0.01% | 1988 |
|
AQR Capital Management's AERI Position: Q4 2022 in Review
AQR Capital Management sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 30,590 shares — an estimated $463K sold.
AQR Capital Management first reported a position in AERI in Q4 2014 and held it in 14 quarters. The position peaked at $1.82M in Q2 2017. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- AQR Capital Management reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- AQR Capital Management sold 30,590 Aerie Pharmaceuticals shares in Q4 2022, an estimated $463K.
- AQR Capital Management first reported a position in Aerie Pharmaceuticals in Q4 2014 and held it in 14 quarters.
- AQR Capital Management's Aerie Pharmaceuticals position peaked at $1.82M in Q2 2017.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on AQR Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.